Multifocal Motor Neuropathy with Conduction Blocks During TNF-alpha Antagonist Therapy in a Patient with Spondyloarthropathy.
10.4078/jrd.2013.20.3.177
- Author:
Rul Bin KIM
1
;
Dong Hoon KANG
;
Sung Yeon LEE
;
Ji Suk HAN
;
Soo Kyung LIM
;
Su Hee SONG
;
Young Il SEO
;
Hyun Ah KIM
Author Information
1. Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Kimha@hallym.ac.kr
- Publication Type:Case Report
- Keywords:
Infliximab;
TNF-alpha antagonist;
Multifocal motor neuropathy with conduction blocks
- MeSH:
Antibodies, Monoclonal;
Guillain-Barre Syndrome;
Human Body;
Humans;
Inflammation;
Polyneuropathies;
Spondylarthropathies;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Journal of Rheumatic Diseases
2013;20(3):177-180
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tumor necrosis factor (TNF)-alpha antagonist has been proven to have benefit for rheumatologic diseases. Because TNF-alpha is not only an important mediator of inflammation in human body, but plays many physiologic roles, it can cause unique adverse effects or complications related to these functions. Adverse effects involving neurological systems, such as Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy with conduction blocks (MMNCB), distal symmetric polyneuropathy, and small fibers neuropathy have been previously reported. However, only several cases of infliximab-associated MMNCB are reported. We report a case of MMNCB which developed while treating spondyloarthropathy with infliximab.
